SCHEMBL497577

SCHEMBL497577

CC(=O)c1ccc(OCc2c(C(C)C)nnn2-c2c(Cl)cccc2Cl)cc1C

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 8/20 0.60
MAOB P27338 6/20 0.39
MAOA P21397 4/20 0.39
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.36
KMT2A Q03164 1/20 0.36
CCNK O75909 1/20 0.36
CCND3 P30281 1/20 0.36
GSK3B P49841 1/20 0.36
CDK7 P50613 1/20 0.36
CDK9 P50750 1/20 0.36
CCNH P51946 1/20 0.36
CDK6 Q00534 1/20 0.36
CDK12 Q9NYV4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL498488 0.94 NR1H4 (0.54) NR1H4MAOBMAOAALDH1A1GAA
SCHEMBL498233 0.87 NR1H4 (0.62) NR1H4MAOBMAOAALDH1A1MAPT
SCHEMBL498139 0.84 NR1H4 (0.57) NR1H4MAPTL3MBTL1MRGPRX4KMT2A
SCHEMBL497662 0.84 NR1H4 (0.56) NR1H4ALDH1A1MAPTMRGPRX4KMT2A
SCHEMBL498129 0.84 NR1H4 (0.68) NR1H4MRGPRX4
SCHEMBL3159242 0.83 NR1H4 (0.55) NR1H4MRGPRX4KMT2ACCNKCCND3
SCHEMBL2770795 0.83 NR1H4 (0.59) NR1H4MAOBMAOAALDH1A1GAA
SCHEMBL496925 0.83 NR1H4 (0.53) NR1H4ALDH1A1GAAMAPTL3MBTL1
SCHEMBL498149 0.83 NR1H4 (0.56) NR1H4ALDH1A1MAPTMRGPRX4KMT2A
SCHEMBL497893 0.82 NR1H4 (0.60) NR1H4CCNKCCND3GSK3BCDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106077-B2 Compounds and methods for modulating FXR ELI LILLY AND COMPANY (US) 2012-01-31 US disclosed
EP-2029558-B1 COMPOUNDS AND METHODS FOR MODULATING FXR LILLY CO ELI (US) 2010-03-10 EP disclosed
US-20090093524-A1 COMPOUNDS AND METHODS FOR MODULATING FXR JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2009-04-09 US disclosed
EP-2029558-A2 COMPOUNDS AND METHODS FOR MODULATING FXR ELI LILLY AND COMPANY (US) 2009-03-04 EP disclosed
WO-2007140174-A2 COMPOUNDS AND METHODS FOR MODULATING FXR ELI LILLY AND COMPANY (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093524-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NR1H4, SLC10A1, FXR1 NR1H4 1/4885MAOB 1668/4885MAOA 3341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.